Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.019
Sell
RSI(14)
45.250
Neutral
STOCH(KDJ)(9,3,3)
12.413
Oversold
ATR(14)
0.156
High Vlolatility
CCI(14)
-116.811
Sell
Williams %R
84.441
Oversold
TRIX(12,20)
-0.073
Sell
StochRSI(14)
44.008
Buy
Synergy CHC Corp
SNYR1.770USD
+0.050+2.91%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
19.92MMarket Cap
6.29P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Synergy CHC Corp
Currency: USD Updated: 2026-02-06Key Insights
Synergy CHC Corp's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 101 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 6.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Synergy CHC Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Synergy CHC Corp Highlights
StrengthsRisks
Synergy CHC Corp. is a provider of consumer healthcare, beauty, and lifestyle products. The Company's brand portfolio includes FOCUSfactor and Flat Tummy. FOCUSfactor is a clinically studied brain health supplement and functional beverage line. Flat Tummy is a lifestyle brand that provides a suite of nutritional products to help women achieve their weight management goals. It has six additional, non-core brands are Hand MD is a complete hand-care brand to help maintain clean and healthy hands while reducing the signs of aging; Perfekt Beauty is in beauty line of products for the eyes, lips, brows, cheeks and skin; Sneaky Vaunt is in lingerie brand with a line of women’s shapewear, bralettes and panties; The Queen Pegasus is in eyelash enhancement products for longer, thicker, natural lashes; Neuragen is in fast-acting topical treatments for neuropathic (nerve) pain, and UrgentRx is in line of fast-acting, portable, powdered over-the-counter medications.
Growing
The company is in a growing phase, with the latest annual income totaling USD 34.83M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 34.83M.
Undervalued
The company’s latest PE is 6.29, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.28M shares, increasing 8.74% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 95.11K shares of this stock.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
6.000
Target Price
+235.20%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Synergy CHC Corp is 6.77, ranking 140 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 8.01M, representing a year-over-year increase of 12.40%, while its net profit experienced a year-over-year increase of 84.01%.
Score
Financials
4.52
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
2.66
Operational Efficiency
10.00
Growth Potential
9.20
Shareholder Returns
7.47
Synergy CHC Corp's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Synergy CHC Corp is 7.74, ranking 50 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 6.29, which is 182.92% below the recent high of 17.78 and 2.82% above the recent low of 6.11.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 101/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Synergy CHC Corp is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 7.00, with a high of 7.00 and a low of 7.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
6.000
Target Price
+235.20%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Synergy CHC Corp
SNYR
2
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Synergy CHC Corp is 5.96, ranking 134 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 2.05 and the support level at 1.60, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.778
Sell
MA10
1.842
Sell
MA20
1.836
Sell
MA50
1.862
Sell
MA100
2.105
Sell
MA200
2.371
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Synergy CHC Corp is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 11.36%, representing a quarter-over-quarter increase of 159.62%. The largest institutional shareholder is The Vanguard, holding a total of 95.11K shares, representing 0.85% of shares outstanding, with 227.38% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Gowan Private Equity, Inc.
Knight Therapeutics (Barbados), Inc.
Ross (Jack)
Gratia Capital, LLC
Heartland Advisors, Inc.
Dunhill Distribution Group, Inc.
Gowan Capital, Inc.
SoRelle (James Paul)
Warberg Asset Management LLC
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Synergy CHC Corp is 2.64, ranking 125 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+58.07%
240-Day Volatility
+157.20%
Return
Best Daily Return
60 days
+8.33%
120 days
+14.15%
5 years
--
Worst Daily Return
60 days
-11.21%
120 days
-21.23%
5 years
--
Sharpe Ratio
60 days
-1.22
120 days
-1.48
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+58.07%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
-0.90
3 years
--
5 years
--
Skewness
240 days
+0.25
3 years
+18.33
5 years
--
Volatility
Realised Volatility
240 days
+157.20%
5 years
--
Standardised True Range
240 days
+14.83%
5 years
--
Downside Risk-Adjusted Return
120 days
-192.76%
240 days
-192.76%
Maximum Daily Upside Volatility
60 days
+59.13%
Maximum Daily Downside Volatility
60 days
+48.33%
Liquidity
Average Turnover Rate
60 days
+0.99%
120 days
+11.33%
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--
Peer Comparison
Pharmaceuticals
Synergy CHC Corp
SNYR
6.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
9.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
